Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 9/20 | 0.45 |
| ▸ | KLK7 | P49862 | 3/20 | 0.37 |
| ▸ | TOP2A | P11388 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TLR4 | O00206 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6520754 | 1.00 | HPGD (0.45) | HPGDKLK7TOP2ACYP2C9TLR4 | |
| SCHEMBL6520750 | 1.00 | HPGD (0.45) | HPGDKLK7TOP2ACYP2C9TLR4 | |
| SCHEMBL10021271 | 0.93 | HPGD (0.45) | HPGDKLK7TOP2AACACBKMT2A | |
| SCHEMBL14340375 | 0.88 | HPGD (0.45) | HPGDKLK7TOP2AMAPTKMT2A | |
| SCHEMBL7910505 | 0.85 | HPGD (0.42) | HPGDCYP2C9TLR4ALDH1A1LMNA | |
| SCHEMBL7910499 | 0.85 | HPGD (0.42) | HPGDCYP2C9TLR4ALDH1A1LMNA | |
| SCHEMBL7910502 | 0.85 | HPGD (0.42) | HPGDCYP2C9TLR4ALDH1A1LMNA | |
| SCHEMBL9359552 | 0.83 | HPGD (0.37) | HPGDCYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL7907306 | 0.81 | HPGD (0.44) | HPGDCYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL7907302 | 0.81 | HPGD (0.44) | HPGDCYP2C9ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1179522-B1 | Liquid crystalline compound having a difluoropropyleneoxy group as bonding group, liquid crystal composition and liquid crystal display element | CHISSO CORP (JP) | 2005-12-07 | — | — | EP | claimed |
| EP-1179522-B1 | Liquid crystalline compound having a difluoropropyleneoxy group as bonding group, liquid crystal composition and liquid crystal display element | CHISSO CORP (JP) | 2005-12-07 | — | — | EP | disclosed |
| US-6544604-B2 | Large dielectric anisotropy and low refractive anisotropy; for driving elements at low voltage | CHISSO CORPORATION (JP) | 2003-04-08 | — | — | US | disclosed |
| US-20020119260-A1 | Liquid crystalline compound having difluoropropyleneoxy group as bonding group, liquid crystal composition and liquid crystal display element | JNC PETROCHEMICAL CORPORATION (JP) | 2002-08-29 | — | — | US | disclosed |
| EP-1179522-A1 | Liquid crystalline compound having a difluoropropyleneoxy group as bonding group, liquid crystal composition and liquid crystal display element | CHISSO CORPORATION (JP) | 2002-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119260-A1 | Liquid crystalline compound having difluoropropyleneoxy group as bonding group, liquid crystal composition and liquid crystal display element | OCIAD2, HCN2, OCIAD1 | HPGD 4742/4885KLK7 878/4885TOP2A 3688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.